¡Ya estamos en ! Descubre más

Accelerate Diagnostics

AXDX

Capitalización de mercado USD 860 k

Excluida de cotización

AXDX dejó de cotizar en bolsa el 14 de mayo de 2025.

Volver al ranking

Acerca de: Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

Empleados: 107

Salud Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 0%

Negativo 0%

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

TUCSON, Ariz. , May 8, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate" or the Company") today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell its assets through a court supervised sale process.

Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

TUCSON, Ariz. , March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance.

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

TUCSON, Ariz. , March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024.

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

TUCSON, Ariz. , Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024.

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript

Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.

Accelerate Diagnostics, Inc. (AXDX) Q3 2024 Earnings Call Transcript

Zacks Investment Research

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago.

Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

TUCSON, Ariz., Nov. 7, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024.

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m.

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

Zacks Investment Research

Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System

AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.

Accelerate Diagnostics Stock Down Despite FDA Clearance for Arc System

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz. , Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper® CA System (MBT-CA System) and MBT-CA Sepsityper® software extension.

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™